www.laboratoryfocus.ca
Laboratory Focus January/February 2014
Pharma notes
Karun Singh
Helix BioPharma Corp. (Aurora, ON) has commenced patient screening for the sixth dose level cohort in its ongoing Phase 1/2 clinical study of LDOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the fifth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the trial steering committee. The study is an open-label study to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study commenced with a starting dose of 0.12 micrograms of L-DOS47 per kilogram of patient body weight in the first patient cohort. Patients to be enrolled in the sixth cohort will receive the next L-DOS47 dose level as planned in the study protocol, which is 0.78 micrograms of L-DOS47 per kilogram of patient body weight. Qu Biologics Inc. (Vancouver, BC) has been granted its second broad Australian patent for the targeted treatment of various cancers, including all common cancers. Australian Patent No.2007308721 involves the tissue-targeted activation of the immune response to treat cancers. The patent encompasses formulations of killed viruses to stimulate this site specific anti-tumour immune response. Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from inactivated bacteria and viruses aimed at stimulating the body’s own immune system against cancer and autoimmune disease. The company’s SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.
Sirona Biochem Corp. (Vancouver, BC) has signed a global exclusive licensing agreement with Obagi Medical Products for the commercialization of its skin lightening compound
TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products. As part of the agreement Sirona will
transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the final commercial products. Target
launch of products including Sirona Biochem’s TFC-849 is Q4 2014 for Obagi. The exclusive license for TFC849 is valid for the global Valeant Pharmaceuticals family of companies.
Quality Products for Your Lab at Affordable Prices!
Millipore Replacement Cartridges/Products
SAVE 10%
Water Filtration Products *Millipore is used for identification purposes only Cat. No. WYV-AMCMCDD02
*Millipore Cat. No. CFOF01205
Description REPLACEMENT KIT 4 BOWL Milli-Q System
Price
Special
$479.00
$431.10 $511.20
WYV-AMCCF2203
CDFC02203
Carbon Filters 55 cm (22 in), 3/pk
$568.00
WYV-AMCMB2202
CPMB02202
Ion-Exchange Cartridge 55 cm (22 in.), 2/pk
$543.00
$488.70
WYV-AMCOS2201
CDEX02201
Organic Scavenger Cartridge 55 cm (22 in.), 1/pk
$318.00
$286.20 $304.20
WYV-AMCPT4001
PR0GTL0S1US
PT-TL1 Long Pretreatment Pack, 1/pk
$338.00
WYV-AMCPT6001
PRPK0L0S1US
PT-60 Pre-System Pretreatment Pack, 1/pk
$332.00
$298.80
WYV-AMCQP0101
CPMQ004R1
High Purity Polishing HP-Pack 1 (RO & Distilled Feed), 1/pk
$441.00
$396.90 $351.90
WYV-AMCPT0101
CPR0P0402
RO Pretreatment PT-Pack, Double Sided, 1/pk
$391.00
WYV-AMCHP1001
QGARD00R1
ULTRA Brand HP Pack R1 (RO & Distilled Feed), 1/pk
$224.00
$201.60
WYV-AMCFP1001
QTUM000EX
ULTRA Brand FP Pack EX, 1/pk
$270.00
$243.00
WYV-AMCPT2001
PR0G00002
ULTRA Brand Pretreatment PT-Pack 20, 1/pk
$283.00
$254.70
Quality Filters from Wyvern Scientific
High Quality - Competitive Price!
5
Valid until December 31, 2014
www.mandel.ca 1-888-883-3636 info@mandel.ca
